LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth.
Our laboratory has recently developed a lipopolyplex consisting of DOTAP:cholesterol liposomes, protamine sulfate, and plasmid DNA (LPD) that provides improved systemic gene delivery compared with lipoplex following tail vein injection in mice. Because endothelial cells are the primary cells transfected in the lung, it was hypothesized that LPD might be an effective vector for gene therapy of pulmonary metastases. This hypothesis was examined by testing the efficacy of cytokine (IL-12) and tumor suppressor (p53) strategies for treatment of an experimental model of pulmonary metastasis in C57Bl/6 mice. Surprisingly, all LPD complexes including those containing an 'empty' plasmid provided a potent (>50% inhibition) and dose-dependent antitumor effect, compared with dextrose-treated controls. In addition, i.v. injections of LPD containing 'empty' plasmid also inhibited tumor growth in a subcutaneous model of C3 fibrosarcomma. The antitumor effect correlated well with a strong and rapid proinflammatory cytokine (TNF-alpha, IL-12 and IFN-gamma) response. Naked plasmid DNA did not elicit a cytokine response and the response required assembly of DNA into a lipoplex or the LPD lipopolyplex. Except for the heart, elevated levels of cytokine were observed in all organs (lung, liver, kidney and spleen) where LPD is known to have gene transfer activity. Methylation of immune-stimulatory CpG motifs in the plasmid component of LPD inhibited the proinflammatory cytokine response as well as the antitumor effect of LPD in both tumor systems. This suggests that i. v. administration of LPD elicits a systemic proinflammatory cytokine response that mediates the antitumor activity of the lipopolyplex. In addition, the antitumor activity was not observed in SCID mice suggesting a possible role for B or T lymphocytes in the antitumor response initiated by LPD. This represents the first demonstration that an intravenously administered cationic liposome-based nonviral vector can promote a systemic, Th1-like innate immune response. The immune adjuvant properties of LPD might prove to be suitable for delivering tumor-specific antigens in the context of DNA vaccination.
Whitmore
M
M
Laboratory of Drug Targeting, Department of Pharmacology, University of Pittsburgh School of Medicine, W1351 Biomedical Sciences Tower, Pittsburgh, PA 15261, USA.
Li
S
S
Huang
L
L
D000818:Animals; D002455:Cell Division; D002784:Cholesterol / Q000008:administration & dosage; D016207:Cytokines / Q000378:metabolism*; D004338:Drug Combinations; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage; D005354:Fibrosarcoma / Q000473:pathology / Q000628:therapy*; D007275:Injections, Intravenous; D008081:Liposomes / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D008745:Methylation; D051379:Mice; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D010957:Plasmids; D011479:Protamines / Q000008:administration & dosage*; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage; D019444:Vaccines, DNA / Q000008:administration & dosage*
D016207:Cytokines; D004338:Drug Combinations; D005229:Fatty Acids, Monounsaturated; D008081:Liposomes; D011479:Protamines; D000644:Quaternary Ammonium Compounds; D019444:Vaccines, DNA; D002784:Cholesterol; C070046:1,2-dioleoyloxy-3-(trimethylammonium)propane